Evidence map›Paper›PMID 37953373›Full record

ArticleVirchows Archiv : an international journal of pathology2024

Expression of CD5 in salivary gland tumors: an ancillary marker for carcinoma showing thymus-like differentiation (CASTLE) of the major salivary gland.

Eiichi Sasaki, Hoshino Terada, Naoki Oishi, Akari Iwakoshi, Katsuhiro Masago, Hirokazu Matsushita, Hidetaka Yamamoto, Nobuhiro Hanai, Hisashi Tateyama

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Eiichi SasakiDepartment of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-Ku, Nagoya, Aichi, 464-8681, Japan. sasakia1es@gmail.com.ORCID http://orcid.org/0000-0002-6385-8341
Hoshino TeradaDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
Naoki OishiDepartment of Pathology, University of Yamanashi, Chuo, Japan.
Akari IwakoshiClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Katsuhiro MasagoDepartment of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-Ku, Nagoya, Aichi, 464-8681, Japan.
Hirokazu MatsushitaDivision of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan.
Hidetaka YamamotoDepartment of Pathology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan.
Nobuhiro HanaiDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
Hisashi TateyamaDepartment of Pathology, Clinical Laboratory, Kasugai Municipal Hospital, Kasugai, Japan.
Aichi Cancer Center · JPKasugai Municipal Hospital · JPNational Hospital Organization · JPOkayama University · JPUniversity of Yamanashi · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, cases of carcinoma showing thymus-like differentiation (CASTLE) occurring in major salivary glands have been identified. To assess the diagnostic value of CD5 immunohistochemistry in distinguishing salivary CASTLE from other types of salivary gland tumors, we evaluated CD5 expression in 109 salivary gland tumors, encompassing 23 different histological types, including salivary CASTLE. In addition, we reviewed 10 previously reported cases of salivary CASTLE. Most salivary CASTLE cases (10/11, 91%) showed strong CD5 expression. In contrast, 104 of 108 (96%) non-salivary CASTLE tumors were negative for CD5, while the remaining four tumors (3.7%), all of which were histologically Warthin tumors, showed focal positivity for CD5 with weak to moderate intensity. In conclusion, the findings in this study support the potential use of CD5 immunohistochemistry for distinguishing salivary CASTLE from other histological types of salivary gland tumors. Aberrant CD5 expression in this tumor may be linked to the tumor microenvironment.

Indexed as

Biomarkers, TumorCD5 AntigensImmunohistochemistrySalivary Gland NeoplasmsAdultAgedAged, 80 and overCarcinomaCell DifferentiationDiagnosis, DifferentialFemaleHumansMaleMiddle AgedSalivary GlandsBiomarkers, TumorCD5 AntigensCASTLECD5Intercalated ductIntrasalivary thymic carcinomaNRASWarthin tumor

Identifiers

PMID37953373
OpenAlexW4388616929

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.